Table 2. Secondary endpoints in the ARMIN and control groups.
| Total | ARMIN(N = 5033) | Controls(N = 10 039) | p-value | |
| Number of specific* hospitalizations of patients during the entire follow-up | ||||
| – Median (IQR) | 0 (0, 1) | 0 (0, 1) | 0 (0, 1) | |
| – Mean ± SD | 0.4 ± 0.5 | 0.4 ± 0.5 | 0.4 ± 0.5 | pWilcoxon = 0.860 |
| Utilization of health care in the follow-up observation period (and comparison with the previous year) | ||||
|
Total pharmacy visits Incidence rate/patient year (absolute change from previous year) |
14.6 (+1.1) | 15.5 (+2.0) | 14.1 (+0.6) | pPoisson <0.001 |
|
Visits to different pharmacies Incidence rate/patient year (absolute change from previous year) |
1.2 (−0.8) | 1.1 (−0.8) | 1.2 (−0.8) | pPoisson <0.001 |
|
Total contacts with general practitioners Incidence rate/patient year (absolute change from previous year) |
15.5 (+0.2) | 16.6 (+1.3) | 15.0 (−0.4) | pPoisson <0.001 |
|
Contacts with different general practitioners Incidence rate/patient year (absolute change from previous year) |
1.3 (−0.6) | 1.6 (−0.2) | 1.1 (−0.8) | pPoisson <0.001 |
|
Total contacts with specialists Incidence rate/patient year (absolute change from previous year) |
5.4 (−1.8) | 6.6 (−0.6) | 4.8 (−2.5) | pPoisson <0.001 |
* Specific hospitalizations were defined as admissions potentially related to adverse drug reactions to currently prescribed drugs, according to Meid et al. 2018 (15); pPoisson denotes a group comparison using a Poisson model for the incidence of visits in the follow-up observation period, controlling for the number of events in the previous year.
ARMIN, Medicines Initiative Saxony-Thuringia; IQR, interquartile range; SD, standard deviation